EGFR and non-small cell lung carcinoma: As neratinib was not available, on the basis of the results of the clinical trial LUX-Lung 2, LUX-Lung 3, and LUX-Lung6, involving 32 patients, the 2G EGFR-TKI afatinib was expanded the label by the U.S. Food and Drug Administration (FDA) in 2018 for patients with advanced NSCLC with uncommon EGFR mutations.